Goldman Sachs Group Inc Bluebird Bio, Inc. Transaction History

Goldman Sachs Group Inc

  • $605 Billion
  • Q3 2024

A detailed history of Goldman Sachs Group Inc transactions in Bluebird Bio, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 805,190 shares of BLUE stock, worth $241,557. This represents 0.0% of its overall portfolio holdings.

Number of Shares
805,190
Previous 407,458 97.61%
Holding current value
$241,557
Previous $399,000 4.76%
% of portfolio
0.0%
Previous 0.0%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$0.47 - $1.35 $186,934 - $536,938
397,732 Added 97.61%
805,190 $418,000
Q2 2024

Aug 13, 2024
SELL
$0.85 - $1.26 $232,349 - $344,423
-273,352 Reduced 40.15%
407,458 $399,000
Q1 2024

May 15, 2024
SELL
$0.91 - $1.75 $542,156 - $1.04 Million
-595,776 Reduced 46.67%
680,810 $871,000
Q4 2023

Feb 13, 2024
BUY
$1.32 - $4.83 $680,871 - $2.49 Million
515,812 Added 67.8%
1,276,586 $1.76 Million
Q3 2023

May 14, 2024
SELL
$3.02 - $4.05 $1.56 Million - $2.09 Million
-515,812 Reduced 40.41%
760,774 $2.31 Million
Q3 2023

Nov 14, 2023
SELL
$3.02 - $4.05 $899,458 - $1.21 Million
-297,834 Reduced 28.13%
760,774 $2.31 Million
Q2 2023

May 14, 2024
SELL
$2.79 - $5.03 $1.53 Million - $2.76 Million
-549,153 Reduced 34.16%
1,058,608 $3.48 Million
Q2 2023

Aug 14, 2023
SELL
$2.79 - $5.03 $1.53 Million - $2.76 Million
-549,153 Reduced 34.16%
1,058,608 $3.48 Million
Q1 2023

May 14, 2024
SELL
$3.14 - $8.22 $471,876 - $1.24 Million
-150,279 Reduced 8.55%
1,607,761 $5.11 Million
Q1 2023

May 11, 2023
SELL
$3.14 - $8.22 $471,876 - $1.24 Million
-150,279 Reduced 8.55%
1,607,761 $5.11 Million
Q4 2022

May 14, 2024
BUY
$5.77 - $8.49 $1.51 Million - $2.22 Million
260,977 Added 17.43%
1,758,040 $12.2 Million
Q4 2022

Feb 13, 2023
BUY
$5.77 - $8.49 $1.51 Million - $2.22 Million
260,977 Added 17.43%
1,758,040 $12.2 Million
Q3 2022

May 14, 2024
SELL
$3.75 - $7.39 $1.35 Million - $2.65 Million
-358,817 Reduced 19.33%
1,497,063 $9.48 Million
Q3 2022

Nov 10, 2022
SELL
$3.75 - $7.39 $1.35 Million - $2.65 Million
-358,817 Reduced 19.33%
1,497,063 $9.48 Million
Q2 2022

May 14, 2024
BUY
$2.94 - $5.23 $1.7 Million - $3.03 Million
579,294 Added 45.38%
1,855,880 $7.68 Million
Q2 2022

Aug 15, 2022
SELL
$2.94 - $5.23 $699,555 - $1.24 Million
-237,944 Reduced 11.36%
1,855,880 $7.68 Million
Q1 2022

May 16, 2022
BUY
$4.07 - $10.6 $2.33 Million - $6.07 Million
573,073 Added 37.68%
2,093,824 $10.2 Million
Q4 2021

Feb 14, 2022
BUY
$8.96 - $16.31 $154,282 - $280,841
17,219 Added 1.15%
1,520,751 $15.2 Million
Q3 2021

Nov 10, 2021
BUY
$11.24 - $21.0 $16.9 Million - $31.6 Million
1,503,532 New
1,503,532 $28.7 Million

Others Institutions Holding BLUE

# of Institutions
151
Shares Held
63.4M
Call Options Held
264K
Put Options Held
428K
View Full List

About bluebird bio, Inc.

BLUE Quotes by TradingView
  • Ticker BLUE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,121,800
  • Market Cap $23.1M
  • Description
  • bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...
More about BLUE
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email